Blockchain could galvanize COVID-19 impacted healthcare supply chains: GlobalData

Blockchain technology could prove to be the missing link for global healthcare supply chains exposed by the COVID-19 pandemic in building resilience and galvanizing efficiency, transparency and authenticity, according to market research firm, GlobalData.
The COVID-19 pandemic has wreaked havoc on almost every part of the healthcare industry's supply chains and has rendered many organizations -- especially those who rely heavily on markets such as India and China for raw materials or finished products -- vulnerable, the firm said.
The current outbreak has, therefore, created a "huge stress test" for the healthcare industry and the desperate need for change, said Urte Jakimaviciute, Senior Director of Market Research at GlobalData. "Lack of supply chain efficiency, transparency and authenticity has been an ongoing issue and the root of many challenges faced by the healthcare companies."
GlobalData cited numerous instances of faulty and counterfeit goods entering markets, which has exacerbated and weakened the global fight against COVID-19: faulty China-produced protective masks and testing kits have been reported by EU countries such as Spain and the Netherlands; Australian Border Force has reportedly seized consignments of personal protective equipment (PPE) that was counterfeit or defective; and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has disabled nine domain names and social media accounts that were selling fake or unauthorized COVID-19 products.
Unless all points in the supply chain are transparent, identifying the source of the transgression or verifying the authenticity of the product is difficult, GlobalData said.
According to Jakimaviciute, healthcare organizations, from manufacturers to distributors, could use blockchain-based systems, which would provide an "open, tamper-proof, distributed record of transactions" and, in turn, "increase accuracy and efficiency".
"Blockchain has broad implications for the healthcare industry. More cases have recently emerged due to the need to simplify and improve security and accuracy for cumbersome, inefficient supply chain processes. While it may be too late to incorporate any sizable blockchain-related solutions to manage the impact of the coronavirus on supply chains, as the technology is still in a proof-of-concept stage, blockchain remains as one of the most promising solutions to facilitate data sharing, improve regulatory compliance and adherence with serialization regulations,” Jakimaviciute concluded.
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz.
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance